RETRACTED ARTICLE: Evaluation of prolonged use of statins on the clinical and biochemical abnormalities and ovulation dysfunction in single young women with polycystic ovary syndrome

Seyam, Emaduldin; Gelany, Saad Al; Ghaney, Ahmed A.; Mohamed, Marwa; Youseff, Ayman Moheb; Ibrahim, Emad M.; Khalifa, Eissa; Hefzy, Enas

doi:10.1080/09513590.2017.1418853

Cited by 24 publications

(16 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…26 Seyam et al showed statins such as simvastatin for 6 months by altering sex hormones and blood lipids improve ovulation in women with polycystic ovary syndrome. 27 In the many sections of the ovary gland of BaP groups, we observed reduction in the kinds of follicles especially primordial follicles. These changes have a positive correlation with doses of BaP.…”

Section: Discussionmentioning

confidence: 79%

“…35,36 It was confirmed that Long-term Statins' treatment (Simvastatin, 20 mg daily for 6 months) in women with polycystic ovary syndrome increase progesterone. 27 We administered BaP to pregnant rats at doses 10 and 20 mg/kg and found that prenatal BaP exposure with the increase in MDA and the decrease in the GSH create stress oxidative in the girl offsprings.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Effect of prenatal exposure to Benzo[a]pyrene on ovarian toxicity and reproductive dysfunction: Protective effect of atorvastatin in the embryonic period

Rahmani

Malekshah

Zargari

et al. 2021

Environmental Toxicology

View full text Add to dashboard Cite

As an environmental contaminant, Benzo[a]pyrene (B[a]P; BaP) disrupts the antioxidant signaling and thus leads to the induction of oxidative stress and the damage of DNA in the ovary. low-dose atorvastatin (ATV) has antioxidant and anti-apoptotic properties. The present study aimed to survey the effects of prenatal exposure to BaP on ovarian toxicity and also to investigate the protective role of ATV in reducing ovarian toxicity. In this study, rats were divided into seven groups: control, ATV (10 mg/kg), oil, BaP (10 and 20 mg/kg), and ATV + BaP (10 and 20 mg/kg). BaP and ATV were administrated from gestation day 7-16 (GD7 to GD16), orally. 10 weeks after the birth, female offsprings were examined for oxidative stress markers, sex hormones, ovarian and tubular tissue structure, and the apoptosis markers. Data showed that BaP significantly reduced glutathione, increased malondialdehyde level, and disrupted the tissue structure of the ovary. Moreover, estrogen and progesterone levels significantly decreased in the offsprings rats. Also, BaP increased caspase-3 immunoreactivity. Atorvastatin treatment along with BaP in the embryonic period were able to bring the antioxidant status and sex hormones levels relatively close to normal. Besides, histological findings showed that atorvastatin was able to improve ovarian and oviduct abnormalities caused by BaP. Based on the above studies be concluded that atorvastatin in the embryonic during was able to reduce ovarian damage caused by BaP with antioxidant and anti-apoptotic properties.

show abstract

Section: Discussionmentioning

confidence: 79%

Section: Discussionmentioning

confidence: 99%

Effect of prenatal exposure to Benzo[a]pyrene on ovarian toxicity and reproductive dysfunction: Protective effect of atorvastatin in the embryonic period

Rahmani

Malekshah

Zargari

et al. 2021

Environmental Toxicology

View full text Add to dashboard Cite

show abstract

“…Six studies included statin treatment with simvastatin (20 mg/day) [15,16,19–21,24], two studies included treatment with atorvastatin (20 mg/day) [12,23], one study included atorvastatin (40 mg/day) [13], one study included treatment with rosuvastatin (10 mg/day) [22]. The duration of statin treatment in three studies was 24 weeks [21–24], and in the remaining studies, the duration of treatment was 12 weeks or less than 12 weeks. Three RCTs used intention-to-treat (ITT) analysis [13,14,16].…”

Section: Resultsmentioning

confidence: 99%

The Effect of Statins on Levels of Dehydroepiandrosterone (DHEA) in Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis

Song

Jing

et al. 2019

Med Sci Monit

View full text Add to dashboard Cite

BackgroundCurrently, statins are used to treat polycystic ovary syndrome (PCOS). This systematic review and meta-analysis aimed to investigate the effect of statins on serum or plasma levels of dehydroepiandrosterone (DHEA) in women with PCOS.Material/MethodsDatabases that were searched included PubMed, Embase, and the Cochrane Library from their inception to August of 2018. Published randomized controlled trials (RCTs) were identified that evaluated the impact of statins on plasma DHEA levels in women with PCOS. The Cochrane risk of bias tool was used to assess the quality of the included RCTs. A random-effects model was used to analyze the pooled results.ResultsMeta-analysis was performed on data from ten published studies that included 735 patients and showed that statin treatment could significantly reduce plasma DHEA levels when compared with controls (SMD, −0.43; 95% CI, −0.81–0.06; p=0.02; I2=82%). Statins were significantly more effective than placebo in reducing the levels of DHEAs. Subgroup analysis based on statin type showed that atorvastatin significantly reduced DHEA levels (SMD, −0.63; 95% CI, −1.20 – −0.05; p=0.03; I2=38%) but simvastatin did not significantly reduce DHEA levels (SMD: −0.14; 95% CI, −0.49–0.28; p=0.43; I2=77%). Subgroup analysis based on duration of treatment showed no significant difference between 12 weeks of statin treatment (SMD, −0.61; 95% CI, −1.23–0.02; p=0.06; I2=85%) and 24 weeks (SMD, −0.34; 95% CI −0.95–0.28; p=0.29; I2=83%).ConclusionsMeta-analysis showed that statins significantly reduced the levels of DHEA when compared with placebo in patients with PCOS.

show abstract

“…Another diabetes medication, the dipeptidyl peptidase-4 inhibitor saxagliptin also showed greater efficacy when combined with metformin versus either drug alone in a group of subjects with PCOS and pre-diabetes [89]. Two studies report that the β-Hydroxy β-methylglutaryl-CoA reductase inhibitor simvastatin, generally used for hyperlipidemia and protection from atherosclerotic heart disease, was found to be effective in improving ovarian morphology and cardiometabolic parameters as monotherapy [90] and in combination with metformin [91]. As statins have been linked to increased incidence of type 2 diabetes [92], further understanding of short and long-term effects on glucose metabolism in PCOS are required.…”

Section: No Magic Pill: Explorative Treatment Optionsmentioning

confidence: 99%

Emerging Topics in Cardiometabolic and Psychologic Sequelae, Pathogenesis, and Treatment of Polycystic Ovarian Syndrome: A Review

Shah

2019

Children

View full text Add to dashboard Cite

Polycystic ovarian syndrome (PCOS) is a common endocrine disorder, affecting 6–10% of reproductive age women and influences the reproductive, metabolic, dermatologic, and psychiatric health of affected girls and women. Despite its prevalence, the pathogenesis of the disease is largely unknown, and treatment options are limited. Thus, PCOS has been a ripe area for research in recent years, and novel etiologic pathways, diagnostic parameters, and treatment options are being explored. This review focuses on recent data suggesting pathogenic and therapeutic considerations, as well as the psychiatric and metabolic sequelae of PCOS.

show abstract

RETRACTED ARTICLE: Evaluation of prolonged use of statins on the clinical and biochemical abnormalities and ovulation dysfunction in single young women with polycystic ovary syndrome

Abstract: Long-term Statins' treatment was associated with clear improvement of all PCOS clinical and biochemical abnormalities, in addition to ovarian dysfunction as well.

Cited by 24 publications

References 28 publications

Effect of prenatal exposure to Benzo[a]pyrene on ovarian toxicity and reproductive dysfunction: Protective effect of atorvastatin in the embryonic period

Effect of prenatal exposure to Benzo[a]pyrene on ovarian toxicity and reproductive dysfunction: Protective effect of atorvastatin in the embryonic period

The Effect of Statins on Levels of Dehydroepiandrosterone (DHEA) in Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis

Emerging Topics in Cardiometabolic and Psychologic Sequelae, Pathogenesis, and Treatment of Polycystic Ovarian Syndrome: A Review

Contact Info

Product

Resources

About